scarring | GenomeWeb

scarring

The drug is designed to silence connective tissue growth factor, which is implicated in scarring and fibrosis.

RXi Pharmaceuticals said this week that it has signed a deal giving the European Union distribution rights to its investigational anti-scarring drug RXI-109 to UK-based Ethicor.

This article has been updated to include details about RXi's third quarter financial results.
RXi Pharmaceuticals this week announced that it has begun dosing patients in a phase II trial of its investigational anti-scarring drug RXI-109.

RXi Pharmaceuticals this week released data from a phase I trial of its dermal anti-scarring drug RXI-109, showing that the compound was safe and well-tolerated.

RXi Pharmaceuticals this week announced that its lead drug candidate, the anti-scarring agent RXI-109, was safe and well tolerated in a phase I study, while producing a dose-dependent reduction of its target protein.

Having just raised $16 million through the sale of around 113 million shares, RXi Pharmaceuticals last week said that it now has the financial means to funds its operations, including the phase II development of its lead RNAi drug candidate, into 2015.

RXi Pharmaceuticals has completed patient dosing in the second of two phase I trials of its lead drug candidate, the anti-scarring agent RXI-109, and is on track to initiating a phase II study before the end of the year, the company's top executive said last week.

RXi Pharmaceuticals this week announced that it has started a second double-blind phase I study of its RNAi-based anti-scarring compound RXI-109.

RXi Pharmaceuticals this week announced the pharmacokinetic results of a single dose phase I trial of its intradermal anti-scarring drug RXI-109.

RXi Pharmaceuticals this week announced that it has completed patient dosing in a phase I trial of its first clinical candidate, the RNAi-based dermal scarring drug RXI-109.

Pages

In Science this week: random DNA replication errors play role in cancer, and more.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.